Applications Published 28 March 2001

Published: 21-Dec-2001

The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT).


The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT).

  • Pressurised metered dose inhalers and pharmaceutical aerosol formulations conprising a beta-agonist
    Baker Norton Pharmaceutical 1085856*

  • Cationic amphiphile micellar complexes
    Genzyme 1085857*

  • Transdermal therapeutic system for the administration of candesartan
    Hexal 1085858*

  • Wound treatment through inhibition of adenosine diphosphate ribosyl transferase
    University of Medicine and Dentistry of New Jersey 1085859*

  • Formulations for the treatment of gastro-oesophageal reflux
    Reckitt & Colman 1085860*

  • Inhibitors of nitric oxide synthase
    Advanced Medicine 1085861*

  • Method of treating an autoimmune disorder
    Bryan, Thomas B 1085862*

  • Method of HIV and HPV prophylaxis
    Redox Pharmaceuticals 1085864*

  • Use of cytoprotectants
    Seglen, Per 1085865*

  • Use of benzomorphan derivatives as an analgesic
    Gruenenthal 1085866*

  • Therapeutic combinations of (selected) estrogen receptor modulators (SERM) and growth hormone secretagogues for treating musculoskeletal frailty
    Pfizer 1085867*

  • H1-histamine receptor antagonists
    Advanced Medicine 1085868*

  • Spiropiperidine derivatives as melanocortin recpetor agonists
    Merck 1085869*

  • Multivalent agonists, partial agonists and antagonists of the GABA receptors
    Advanced Medicine 1085870*

  • Quinalozine inhibitors of CGMP phosphodiesterase
    Bristol-Myers Squibb 1085871*

  • Inhibitors of transcription factor NF-g(K)B
    SmithKline Beecham 1085872*

  • Use of an NK-1 receptor antagonist for treating psychiatric disorders
    Merck Sharp & Dohme 1085873*

  • Use of an NK-1 receptor antagonist for treating sexual dysfunctions
    Merck Sharp & Dohme 1085874*

  • Use of an NK-1 receptor antagonist for treating psychiatric disorders
    Merck Sharp & Dohme 1085875*

  • Pharmaceutical compsn with tumour necrosis factor A and 2-methoxyesterone-3-O-sulphamate for inhibition of estrone sulphatase
    Sterix 1085876*

  • Use of a composition comprising and budesonide for the prevention or treatment of an acute condition of asthma
    AstraZeneca 1085877*

  • Use of aminosterol derivatives as chloride ionophores
    Genzyme 1085878*

  • Multibinding agents that modulate the 5-HT transporter
    Advanced Medicine 1085879*

  • Use of alkylating compounds for inhibiting proliferation of arterial smooth muscle cells
    Cerus Corp 1085880*

  • Pharmaceutical compsns containing alpha-tocopheryl-phosphocholine
    Clarion Pharmaceuticals 1085881*

  • Use of genetically engineered antibodies to treat multiple myeloma
    Mayo Foundation for Medical Education and Research 1085882*

  • Pharmaceutical compsn on the basis of erythromycin fatty acid salts for the topical treatment of skin diseases
    Dr August Wolf 1085883*

  • Combination of compounds containing selenium and cytostatic agents
    Biosyn Arzneimittel 1085884*

  • Method for assessing a diabetic's risk of experiencing a diabetes-associated pathological condition
    Fox Chase Cancer Centre 1085885*

  • Protecting neurons from ischaemia
    Societe de Conseils de Recherches et d'Applications Scientifiques 1085886*

  • Novel angiotensin receptor modulators and their uses
    Advanced Medicine 1085887*

  • Multivalent agonists, partial agonists, inverse agonists, and antagonists of the 5-HT 3? receptors
    Advanced Medicine 1085888*

  • Novel therapeutic agents that modulate enodthelin receptors
    Advanced Medicine 1085889*

  • Novel sodium channel drugs and their uses
    Advanced Medicine 1085890*

  • Multibinding inhibitors of topoisomerase
    Advanced Medicine 1085891*

  • Vaccination strategy to prevent and treat cancers
    Sloan-Kettering Institute for Cancer Research 1085892*

  • Phosphodiesterase-V modulator drugs and their uses
    Advanced Medicine 1085893*

  • Beta-3 adrenergic receptor agonists
    Advanced Medicine 1085894*

  • Bradykinin Antagonists
    Advanced Medicine 1085895*

  • Conformationally constrained backbone cyclized somastatin analogues
    Peptor 1085896*

  • ACRP30R1L, a homolog of ACRP30 (30 KD adipocyte complement-related protein)
    SmitrhKline Beecham 1085897*

  • Parasite antigens
    Insearch 1085898*

  • Retinoic acid inducible DNA sequences from lung cells
    Georgetown University 1085899*

  • Use of erythropoietin for the treatment of haemochromatoses
    Roche Diagnostics 1085900*

  • Use of secretin for the treatment of autism and other nerological, behavioural and immunological disorders
    Repligen 1085901*

  • Therapeutic compsns that produce an immune response by altering the antigen
    Altarex 1085902*

  • Egg surface proteins and methods for use for modulating fertility
    The University of Virginia Patent Foundation 1085903*

  • Attentuated negative strand viruses with altered inteferon antagonist activity for use as vaccines and pharmaceuticals
    Mount Sinai School of Medicine of the City University of New York 1085904*

  • Immunotherapeutic compsns and method for the treatment of prostate cancer
    AltaRex 1085905*

  • Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
    Ophidian Pharmaceuticals 1085906*

  • Solution comprising prostaglandins and benzyl alcohol
    Pharmacia & Upjohn 1085907*

  • Recombinant immunotoxin directed against the HIV-1 GP120 envelope glycoprotein
    The Government of the United States of America as represented by the Secretary of the Department of Health and Human Resources 1085908*

  • Methods of altering cardiac cell phenotype
    Collateral Therapeutics 1085910*

  • Sulfonamide inhibitors of aspartyl protease
    Vertx Pharmaceuticals 1086076*

  • Novel antiestrogens, a method for the production thereof and their pharmaceutical application
    Schering 1086077*

  • Neuropeptide Y5 receptor antagonists
    Schering 1086078*

  • Derivatives of hydroxyphenylsulfanylbenzoic and hydroxyphenylsulfanylarylacetic acids
    Leciva 1086079*

  • Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics
    Galderma Research and Development 1086080*

  • Quaternary ammonium compounds as anti-tussive agents
    Nortran Pharmaceuticals 1086081*

  • Arylsubstituted olefinic amines and their use as cholinergic receptors agonists
    RJ Reynolds Tobacco 1086082*

  • Protease inhibitors
    SmithKline Beecham 1086083*

  • Tetraisoquinololine derivatives as modulators of dopamine D3 receptors
    SmithKline Beecham 1086084*

  • Inhibitors of P38
    Vertex Pharmaceuticals 1086085*

  • Imidazoyl derivatives and their use as somastatin receptor ligands
    Societe de Conseils de Recherches et d'Applications Scientifiques 1086086*

  • Crystalline efavirenz
    Du Pont Pharmaceuticals 1086087*

  • Novel neurokinin antagonists, method for the production thereof, and pharmaceutical compsns containing said compound
    Boehringer Ingelheim 1086088*

  • Compsn for the treatment of cancer and colitis ulcerosa as well as the use of a titanium complex and a zinc salt for the preparation of the compsn
    Marstrand, Even 1086090*

  • HIV integrase inhibitors
    Merck 1086091*

  • Benzo(B)thiepine-1,1'-dioxide derivatives, a method for the production thereof, medicaments containing these compounds, and their use
    Aventis Pharma Deutschland 1086092*

  • Tetrahydroquinoline derivatives as glycine antagonists
    Glaxo Wellcome 1086093*

  • Quinoline-aminomethyl-pyridyl derivatives with anti-helicobacter activity Byk Gulden Lomberg Chemische
    Fabrik 1086094*

  • Tetrahydroisoquinoline derivatives as modulators of dopamine D3 receptors
    SmithKline Beecham 1086095*

  • Benzamides with tetrahydrofuranyl substituents as phosphodiesterase 4 inhibitors

    Byk Gulden Lomberg Chemische
    Fabrik 1086096*

  • Sulfonylbenzene compounds as antiinflammatory/analgesic agents
    Pfizer 1086097*

  • Tienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
    Aventis Pharma Deutschland; Genentech 1086098*

  • Sulfonic acid of sulfonylamino N-(heteroarylalkyl)-azaheterocyclylamide compounds
    Aventis Pharmaceuticals 1086099*

  • Beta-carboline compounds
    Societe de Conseils de Recherches et d'Applications Scientifiques 1086100*

  • Acetylcholine enhancers
    Arena Pharmaceuticals 1086101*

  • Fused phenoxymethyl carbapenem antibacterials
    Merck & Co 1086104*

  • Fused azepinone cyclin dependent kinase inhibitors
    The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services 1086105*

  • Furopyridine derivatives and their therapeutic use
    Darwin Discovery 1086106*

  • Artemisinin derivatives, method for the preparation thereof and pharmaceutical compsns containing the same
    Shanghai Institute of Materia Medica, Chinese Academy of Sciences 1086107*

  • Heterobicyclic and tricyclic nitric oxide synthase inhibitors.
    GD Searle & Co 1086108*

  • Process for preparing crystalline salts of amoxycillin
    SmithKline Beecham 1086109*

  • Method for producing alkyl halogenosilanes
    GE Bayer Silicones 1086110*

  • Sulphur orthophosphate compsns, preparation and use
    Rhodia Chemie 1086111*

  • 1-galactose derivatives
    Synsorb Biotech 1086112*

  • Benzothiepine-1,1'-dioxide derivatives, method for producing them, medicaments containing these compounds, and their use
    Aventis Pharma Deutschland 1086113*

  • Morphine-6-glucuronide synthesis
    CeNeS 1086114*

  • Purines and pyrimidines linked to a quencher
    Intergen 1086115*

  • Compsns and methods for the pulmonary delivery of nucleic acids
    Isis Pharmaceuticals 1086116*

  • Cloning and identification of the motilin receptor
    Merck 1086117*

  • Vitamin B12? derivatives and methods for their preparation
    Biotech Australia 1086118*

  • Purification of antibodies
    Gradipore 1086119*

  • Method for preparing virus-safe pharmaceutical compsns.
    Suomen Punainen Risti Veripalvelu 1086120*

  • Non-enzymatic chemical amidation process
    Magainin Pharmaceuticals 1086121*

  • Pyrazinone protease inhibitors
    3-Dimensional Pharmaceuticals 1086122*

  • Solution-phase ELIZA
    Immco Diagnostics 1086123*

  • Novel cyclosporins
    C-Chem 1086124*

  • Respiratory nitrate reductase alpha subunit
    SmithKline Beecham 1086125*

  • Cell-permeable peptide
    The Queen's University of Belfast 1086126*

  • Novel compounds
    SmithKline Beecham 1086127*

  • Plant protein with repeated WD40 motifs, nucleic acid coding for said protein, and uses thereof
    Centre National de la Recherche Scientifiques 1086128*

  • Anti-angiogenic proteins and methods of use thereof
    Beth Israel Deaconess Medical Centre 1086129*
    See more

    • You may also like

    Finance

    Shilpa Medicare opens flow chemistry manufacturing centre

    Read more
    The flow chemistry centre of excellence includes more than 100 R&D and manufacturing scientists

    Trending Articles

    1. Thermo Fisher Scientific highlights its new accelerator drug development solutions at CPHI Frankfurt 2025 The company has also announced a collaboration with OpenAI as well as a new digital toolbox, OSDPredict, which combines AI and machine learning models to predict formulation behaviour in small-molecule development
    2. Merck Life Science announces closure of Arklow facility Merck has said it will close the plant in Co Wicklow, Ireland, by the end of 2028, with the loss of 100 jobs
    3. Agarose Bead Technologies marks 25 years with $10m global expansion plan The Spanish agarose resin specialist will expand into the US and India, invest in scalable bioprocessing technologies and enhance sustainability across its European facilities to meet growing demand for advanced therapy purification
    4. Aseptic spray drying: Transforming biotherapeutics for a new era With interest in aseptic spray drying on the rise in the pharmaceutical industry, Dr Kevin Robinson spoke to GEA’s David Costes about how the company is combining process, engineering and technological expertise with market insights to provide a safe, reliable and high-performance technology for advanced biotherapeutic powder applications
    5. Sheffield University’s Energy Innovation Centre advances sustainable aviation Precision Anton Paar instruments support cutting-edge SAF research

    You may also like

    Finance

    Shilpa Medicare opens flow chemistry manufacturing centre

    The flow chemistry centre of excellence includes more than 100 R&D and manufacturing scientists
    Manufacturing

    Frontline innovation: dispatches from the show floor at CPHI Frankfurt (part III)

    The third instalment from the CPHI Frankfurt show floor explores practical approaches and fresh perspectives on scale-up, tech transfer, and manufacturing innovation across the pharmaceutical sector
    Research & Development

    Immunology CRO reports shift to autoimmunity projects

    RoukenBio reports a sharp rise in autoimmunity drug development projects and an almost 50% decrease in immuno-oncology (I-O) studies, showcasing the shift in drug development trends
    Research & Development

    Merck partners with Promega to advance 3D cell drug discovery technologies

    Partnership combines Merck’s chemistry and organoid expertise with Promega’s assay technologies
    Manufacturing

    OPTIMA machinery USA Corporation marks 40 years of growth and innovation in the US

    OPTIMA machinery USA Corporation, a subsidiary of the German-based OPTIMA Packaging Group, is celebrating 40 years of successful operations in the United States
    Manufacturing

    Streamlining bioconjugation for next-generation ADC development

    Abzena’s proprietary ThioBridge™ technology delivers precision, scalability, and enhanced stability for antibody-drug conjugates
    Regulatory

    TurboFil offers industry-leading glove testing systems

    Partnership with RAVONA delivers precision and compliance in aseptic environments
    Subscribe now